{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:12:54Z","timestamp":1787620374269,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The fibroproliferative stage and persistent inflammation of acute respiratory distress syndrome (ARDS) are key factors leading to either the resolution of the syndrome or fibrosis. Previous studies suggest that a corticosteroid therapy promotes the evolution of ARDS toward an adapted repair process whereas others suggest that this therapy increases the risk of death if it starts more than 14\u00a0days after ARDS onset. Since the efficacy and safety of delayed 2\u00a0mg\/kg methylprednisolone therapy in patients with ARDS is a matter of debate, we performed this observational multicentric retrospective study. We analysed the data of 392 patients with ARDS who received 2\u00a0mg\/kg methylprednisolone therapy. The primary endpoint was mortality six months after 2\u00a0mg\/kg methylprednisolone therapy was started. The secondary endpoints included mortality 60\u00a0days after the corticosteroid therapy initiation and the number of ventilator-free days (VFDs) and intensive care unit (ICU)-free days. We investigated the occurrence of complications such as ventilator-acquired pneumonia (VAP), septic shock and gastrointestinal bleeding arising after the start of the protocol. A total of 189 (48.2%) patients received 2\u00a0mg\/kg methylprednisolone therapy within the first 14\u00a0days of ARDS onset. A total of 203 (51.8%) patients received it more than 14\u00a0days included post-ARDS-onset. The mortality rate six months after the initiation of 2\u00a0mg\/kg methylprednisolone therapy was 51.9% in the early initiation group and 52.2% in the late initiation group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.942). The mortality rate 60\u00a0days after the initiation of 2\u00a0mg\/kg methylprednisolone therapy was 47.1% in the early group and 47.3% in the late group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.968). There was no significant difference in the number of VFDs (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.336) or ICU-free days (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.175) 60\u00a0days after the start of the 2\u00a0mg\/kg protocol. Initiating the protocol 14\u00a0days after the onset of ARDS seemed to be associated with more complications (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Late initiation was associated with greater occurrence of VAP (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.018) or gastrointestinal bleeding (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.012). These results suggest that an initiation of 2\u00a0mg\/kg methylprednisolone therapy after 14\u00a0days from ARDS onset is not associated with an increased risk of death as compared with initiation prior to day 14. Delayed 2\u00a0mg\/kg methylprednisolone therapy in patients with persistent ARDS should be considered.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-22142-8","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:18:49Z","timestamp":1761913129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early versus late 2\u00a0mg\/kg methylprednisolone therapy in ARDS"],"prefix":"10.1038","volume":"15","author":[{"given":"Justine","family":"Verch\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Barrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Carvelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Velly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bruder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lagier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Guervilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Loundou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Peres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Forel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"8","key":"22142_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2016.0291","volume":"315","author":"G Bellani","year":"2016","unstructured":"Bellani, G. et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315(8), 788\u2013800 (2016).","journal-title":"JAMA"},{"issue":"14","key":"22142_CR2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1011802","volume":"364","author":"MS Herridge","year":"2011","unstructured":"Herridge, M. S. et al. Functional disability 5 years after acute respiratory distress syndrome. N. Engl. J. Med. 364(14), 1293\u20131304 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"22142_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1196\/annals.1321.004","volume":"1024","author":"GU Meduri","year":"2004","unstructured":"Meduri, G. U. & Yates, C. R. systemic inflammation-associated glucocorticoid resistance and outcome of ARDS. Ann. N. Y. Acad. Sci. 1024(1), 24\u201353 (2004).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"22142_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","volume":"8","author":"J Villar","year":"2020","unstructured":"Villar, J. et al. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir. Med. 8(3), 267\u2013276 (2020).","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"22142_CR5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1378\/chest.06-2100","volume":"131","author":"GU Meduri","year":"2007","unstructured":"Meduri, G. U. et al. Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 131(4), 954\u2013963 (2007).","journal-title":"Chest"},{"issue":"2","key":"22142_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jama.280.2.159","volume":"280","author":"GU Meduri","year":"1998","unstructured":"Meduri, G. U. et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA 280(2), 159\u2013165 (1998).","journal-title":"JAMA"},{"issue":"11","key":"22142_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans, L. et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 47(11), 1181\u20131247 (2021).","journal-title":"Intensive Care Med."},{"issue":"21","key":"22142_CR8","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","volume":"388","author":"PF Dequin","year":"2023","unstructured":"Dequin, P. F. et al. Hydrocortisone in severe community-acquired pneumonia. N. Engl. J. Med. 388(21), 1931\u20131941 (2023).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"22142_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with covid-19. N. Engl. J. Med. 384(8), 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"22142_CR10","doi-asserted-by":"crossref","unstructured":"Steinberg, KP et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. 354(16), 1671\u201384 (2006).","DOI":"10.1056\/NEJMoa051693"},{"issue":"1","key":"22142_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1164\/rccm.202311-2011ST","volume":"209","author":"N Qadir","year":"2024","unstructured":"Qadir, N. et al. An update on management of adult patients with acute respiratory distress syndrome: An official american thoracic society clinical practice guideline. Am. J. Respir. Crit. Care Med. 209(1), 24\u201336 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"22142_CR12","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1097\/CCM.0000000000006172","volume":"52","author":"D Chaudhuri","year":"2024","unstructured":"Chaudhuri, D. et al. Focused update: Guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit. Care Med. 52(5),\u00a0e219\u2013e233 (2024).","journal-title":"Crit. Care Med."},{"issue":"23","key":"22142_CR13","first-page":"2526","volume":"307","author":"The ARDS Definition Task Force*","year":"2012","unstructured":"The ARDS Definition Task Force*. Acute respiratory distress syndrome: The Berlin definition. JAMA 307(23), 2526\u20132533 (2012).","journal-title":"JAMA"},{"issue":"7","key":"22142_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00134-023-07050-7","volume":"49","author":"G Grasselli","year":"2023","unstructured":"Grasselli, G. et al. ESICM guidelines on acute respiratory distress syndrome: Definition, phenotyping and respiratory support strategies. Intensive Care Med. 49(7), 727\u2013759 (2023).","journal-title":"Intensive Care Med."},{"issue":"1","key":"22142_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.beth.2006.05.002","volume":"38","author":"RI Parker","year":"2007","unstructured":"Parker, R. I. & Hagan-Burke, S. Useful effect size interpretations for single case research. Behav. Ther. 38(1), 95\u2013105 (2007).","journal-title":"Behav. Ther."},{"issue":"2","key":"22142_CR16","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/cc11312","volume":"16","author":"JM Forel","year":"2012","unstructured":"Forel, J. M. et al. Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy. Crit. Care 16(2), R65 (2012).","journal-title":"Crit. Care"},{"issue":"5","key":"22142_CR17","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1378\/chest.111.5.1306","volume":"111","author":"AS Headley","year":"1997","unstructured":"Headley, A. S., Meduri, G. U. & Tolley, E. Infections and the Inflammatory response in acute respiratory distress syndrome. Chest 111(5), 1306\u20131321 (1997).","journal-title":"Chest"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22142-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:18:51Z","timestamp":1761913131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22142-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22142"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22142-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38167"}}